Double-Drug attack on Hard-to-Treat cancers

NCT ID NCT07704866

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests a combination of two experimental drugs, FG-M108 and FG-B901, in people with advanced solid tumors that have a specific marker called Claudin 18.2. Participants must have tumors that have worsened despite standard treatments or for which no standard therapy exists. The trial aims to find a safe dose and see if the combination can shrink tumors or slow their growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
two experimental drugs called FG-M108 and FG-B901
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the drugs may not prove effective or may cause significant side effects. The results may not apply to all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLAUDIN 18.2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Harbin Medical University Cancer Hospital

    Ha’erbin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Hospital of China Medical University

    Shenyang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.